Rugocrixan

AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively[1].

Product Specifications

CAS Number

[911715-90-7]

Product Name Alternative

AZD8797; KAND567

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

CX3CR1; CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/AZD8797.html

Purity

99.54

Solubility

DMSO : ≥ 150 mg/mL

Smiles

CC(C)C[C@@H](NC1=NC(S[C@@H](C)C2=CC=CC=C2)=NC3=C1SC(N)=N3)CO

Molecular Formula

C19H25N5OS2

Molecular Weight

403.56

Precautions

H315, H319, H335

References & Citations

[1]Cederblad L, et al. AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor. Biochem J. 2016 Mar 1;473 (5) :641-9.|[2]Ridderstad Wollberg A, et al. Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. Proc Natl Acad Sci U S A. 2014 Apr 8;111 (14) :5409-14.|[3]Sofia Karlströ, et al. Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1) . J Med Chem. 2013 Apr 25;56 (8) :3177-90.